MTOR and metabolic dysfunction-associated steatotic liver disease: Studies have found that HUCMSCs can promote autophagy by suppressing the expression of mTOR and P62, and promoting the levels of AMPK and LC3BII/α, thereby accelerating the degradation of body fat and alleviating the symptoms of MASLD (53).